44. 多発血管炎性肉芽腫症 [臨床試験数:84,薬物数:88(DrugBank:22),標的遺伝子数:13,標的パスウェイ数:37

Searched query = "Wegener granulomatosis", "Multiple vasculitis granulomatous disease", "Granulomatosis with polyangiitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-003162-25-BE06/07/201501/06/2015Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome)
MedDRA version: 20.0Level: LLTClassification code 10018701Term: Granulomatous diseaseSystem Organ Class: 100000004867
MedDRA version: 20.0Level: LLTClassification code 10014956Term: Eosinophilic granulomaSystem Organ Class: 100000004864
MedDRA version: 20.0Level: LLTClassification code 10072580Term: Granulomatous polyangiitisSystem Organ Class: 100000004866
MedDRA version: 20.1Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000004870
MedDRA version: 20.0Level: LLTClassification code 10056218Term: Necrotising granulomatous vasculitisSystem Organ Class: 100000004866
MedDRA version: 20.0Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855
MedDRA version: 20.0Level: LLTClassification code 10036023Term: PolyangiitisSystem Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: SB-240563 (mepolizumab)
Product Code: SB-240563 (mepolizumab)
INN or Proposed INN: Mepolizumab
Other descriptive name: MEPOLIZUMAB
GlaxoSmithKline Research LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
115Phase 3United States;Canada;Belgium;Germany;United Kingdom;Japan
2EUCTR2014-003162-25-DE26/02/201509/12/2014Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard-of-care Therapy) Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome)
MedDRA version: 20.0Level: LLTClassification code 10018701Term: Granulomatous diseaseSystem Organ Class: 100000004867
MedDRA version: 21.1Level: LLTClassification code 10072580Term: Granulomatous polyangiitisSystem Organ Class: 100000004866
MedDRA version: 21.0Level: LLTClassification code 10014956Term: Eosinophilic granulomaSystem Organ Class: 100000004864
MedDRA version: 20.1Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000004870
MedDRA version: 21.1Level: LLTClassification code 10056218Term: Necrotising granulomatous vasculitisSystem Organ Class: 100000004866
MedDRA version: 21.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855
MedDRA version: 21.1Level: LLTClassification code 10036023Term: PolyangiitisSystem Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: SB-240563 (mepolizumab)
Product Code: SB-240563 (mepolizumab)
INN or Proposed INN: Mepolizumab
Other descriptive name: MEPOLIZUMAB
GlaxoSmithKline Research LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
115Phase 3France;Canada;Belgium;Germany;United Kingdom;Japan
3EUCTR2012-004385-17-ES28/01/201405/12/2013Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophilic Granulomatosis with Polyangiitis.A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. Treatment of Eosinophilic Granulomatosis with Polyangiitis inSubjects Receiving Standard of Care Therapy.
MedDRA version: 14.1Level: LLTClassification code 10018701Term: Granulomatous diseaseSystem Organ Class: 100000004867
MedDRA version: 14.1Level: LLTClassification code 10072580Term: Granulomatous polyangiitisSystem Organ Class: 100000004866
MedDRA version: 14.1Level: LLTClassification code 10014956Term: Eosinophilic granulomaSystem Organ Class: 100000004864
MedDRA version: 14.1Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000004870
MedDRA version: 14.1Level: LLTClassification code 10056218Term: Necrotising granulomatous vasculitisSystem Organ Class: 100000004866
MedDRA version: 14.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855
MedDRA version: 14.1Level: LLTClassification code 10036023Term: PolyangiitisSystem Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Mepolizumab
Product Code: SB-240563
INN or Proposed INN: Mepolizumab
Other descriptive name: Recombinant humanized monoclonal antibody specific for human IL-5
GlaxoSmithKline, S.A.NULLNot RecruitingFemale: yes
Male: yes
130Phase 3France;United States;Canada;Belgium;Spain;Germany;Japan;Italy;United Kingdom
4EUCTR2012-004385-17-DE07/01/201425/10/2013Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophilic Granulomatosis with Polyangiitis.A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. Treatment of Eosinophilic Granulomatosis with Polyangiitis inSubjects Receiving Standard of Care Therapy.
MedDRA version: 20.0Level: LLTClassification code 10018701Term: Granulomatous diseaseSystem Organ Class: 100000018094
MedDRA version: 20.0Level: LLTClassification code 10014956Term: Eosinophilic granulomaSystem Organ Class: 100000109234
MedDRA version: 20.0Level: LLTClassification code 10072580Term: Granulomatous polyangiitisSystem Organ Class: 100000140455
MedDRA version: 20.0Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000171039
MedDRA version: 20.0Level: LLTClassification code 10056218Term: Necrotising granulomatous vasculitisSystem Organ Class: 100000140455
MedDRA version: 20.0Level: LLTClassification code 10036023Term: PolyangiitisSystem Organ Class: 100000023163
MedDRA version: 20.0Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000015470;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Mepolizumab
Product Code: SB-240563
INN or Proposed INN: Mepolizumab
Other descriptive name: Recombinant humanized monoclonal antibody specific for human IL-5
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
130Phase 3France;United States;Canada;Belgium;Spain;Germany;Japan;Italy;United Kingdom
5EUCTR2012-004385-17-IT02/01/201411/11/2013Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophilic Granulomatosis with Polyangiitis.A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. Treatment of Eosinophilic Granulomatosis with Polyangiitis inSubjects Receiving Standard of Care Therapy.
MedDRA version: 16.1Level: LLTClassification code 10018701Term: Granulomatous diseaseSystem Organ Class: 100000004867
MedDRA version: 16.1Level: LLTClassification code 10072580Term: Granulomatous polyangiitisSystem Organ Class: 100000004866
MedDRA version: 16.1Level: LLTClassification code 10014956Term: Eosinophilic granulomaSystem Organ Class: 100000004864
MedDRA version: 16.1Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000004870
MedDRA version: 16.1Level: LLTClassification code 10056218Term: Necrotising granulomatous vasculitisSystem Organ Class: 100000004866
MedDRA version: 16.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855
MedDRA version: 16.1Level: LLTClassification code 10036023Term: PolyangiitisSystem Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Mepolizumab
Product Code: SB-240563
INN or Proposed INN: Mepolizumab
Other descriptive name: Recombinant humanized monoclonal antibody specific for human IL-5
GlaxoSmithKline Research & Development LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
130United States;France;Canada;Spain;Belgium;Germany;United Kingdom;Japan;Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2012-004385-17-BE22/11/201304/10/2013Study of mepolizumab versus placebo in addition to standard of care for the treatment of Eosinophilic Granulomatosis with Polyangiitis.A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy. Treatment of Eosinophilic Granulomatosis with Polyangiitis inSubjects Receiving Standard of Care Therapy.
MedDRA version: 17.1Level: LLTClassification code 10018701Term: Granulomatous diseaseSystem Organ Class: 100000004867
MedDRA version: 17.1Level: LLTClassification code 10014956Term: Eosinophilic granulomaSystem Organ Class: 100000004864
MedDRA version: 17.1Level: LLTClassification code 10072580Term: Granulomatous polyangiitisSystem Organ Class: 100000004866
MedDRA version: 17.1Level: LLTClassification code 10014957Term: Eosinophilic granulomatous vasculitisSystem Organ Class: 100000004870
MedDRA version: 17.1Level: LLTClassification code 10056218Term: Necrotising granulomatous vasculitisSystem Organ Class: 100000004866
MedDRA version: 17.1Level: LLTClassification code 10068462Term: Eosinophilic asthmaSystem Organ Class: 100000004855
MedDRA version: 17.1Level: LLTClassification code 10036023Term: PolyangiitisSystem Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Mepolizumab
Product Code: SB-240563
INN or Proposed INN: Mepolizumab
Other descriptive name: Recombinant humanized monoclonal antibody specific for human IL-5
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
130Phase 3France;United States;Canada;Spain;Belgium;Germany;Japan;Italy;United Kingdom